Tirzepatide emerges a groundbreaking treatment agent for individuals struggling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://allenbddf580575.blogofchange.com/41195649/tirzepatide-a-new-frontier-in-diabetes-treatment